M.C. Bene, G. Castoldi, W. Knapp, W.D. Ludwig, E. Matutes, A. Orfao, M.B. Van’t VeerEuropean group for the immunological characterization of leukemias. Disease definition. Acute myeloid leukemia (AML) is a group of neoplasms arising from precursor cells committed to the myeloid cell-line differentiation. ORPHANET USER SATISFACTION SURVEY Welcome to the Orphanet User Satisfaction Survey Your opinion is essential in improving the services.

Author: Fenrilmaran Vokus
Country: Cameroon
Language: English (Spanish)
Genre: Music
Published (Last): 7 March 2010
Pages: 71
PDF File Size: 4.70 Mb
ePub File Size: 6.53 Mb
ISBN: 608-2-84687-611-9
Downloads: 4793
Price: Free* [*Free Regsitration Required]
Uploader: Zura

Pathogenesis of AML is still unclear but a two-hit model has been suggested leuemie the probable mechanism for leukemogenesis.

After morphological examination, immunophenotyping of leukemic cells, cytogenetic and molecular analysis should be performed.

Health care resources for this disease Expert centres Diagnostic tests Patient organisations 43 Orphan drug s Contact Help Who are we? Top of the page – Article Outline.

Only comments written in English can be processed.

With 13, new cases. Tasigna USD 57 millions est disponible dans plus de 50 pays et progresse en [ Summary and related texts. Personal information regarding our website’s visitors, including their identity, is confidential.

Chez environ un quart des aogue [ Previous Article Intoxication par brunneoincarnata: Check this box if you wish to receive a copy of your message. Additional information Further information on this disease Classification s 2 Gene s 2 Other website s 3. You can move this window by clicking on the headline.


LeucĂ©mie aiguĂ« biclonale – ScienceDirect

Health care leucfmie for this disease Expert centres Diagnostic tests Patient organisations 45 Orphan drug s Easy bruising or hemorrhagic diathesis epistaxis, gums bleeding, hematuria, petechiae, metroragia are frequently observed. Prognosis varies widely according to cytogenetics, molecular findings, response to induction treatment and age, between others. To understand this in the context of cancer biology, we are currently.

Access to the leucemis text of this article requires a subscription. While data supporting progenitor cells committed to specific myeloid cell type has been reported, other studies argue in favor for a more immature stem.

It should not be summed up with the orange entries The leucemje is wrong or of bad quality. You helped to increase the quality of our service.

In around a quarter of patients presenting the most. Differential diagnosis Differential diagnosis includes megaloblastic anaemia, myelodysplastic syndromes, acute lymphoblastic leukemia, acute biphenotypic leukemia, chronic myeloid leukemia myeloid blast phaseand metastases of tumors such rhabdomyosarcoma and neuroblastoma see these terms. For all other comments, please send your remarks via contact us.

Other search option s Alphabetical list. Detailed information Article for general public Deutsch The main clinical picture consists of a short time period with pallor, fatigue, fever, infections and hemorrhages.

The trial leicemie patients with [ In Canada, a cu te my elo id leukemia A ML is t he leading [ Borden, principal investigator at IRIC, will lead a. Only comments written in English can be processed. If you want to subscribe to this journal, see our rates You can purchase this item in Pay Per View: Tasigna USD 57 million is available in over 50 countries and gaining as a new [ The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.


Choissez votre continent et pays

Tasigna nilotinib is awaiting regulatory decisions in the US, Europe and Switzerland as a new targeted cancer therapy for patients. That means that AML could be the consequence leuxemie at least 2 different types of gene mutations. Etiology Pathogenesis of AML is still unclear but a two-hit model has been suggested as the probable mechanism for leukemogenesis.

These doses have been chosen on the basis of the results of the Phase I trials in. Although, AML can occur at any age, it is typically a disease affecting elder people, usually more than 65 years.